EMI (Encore Medical) EBITDA Margin %: -25.71% (As of Dec. 2025)


What is Encore Medical EBITDA Margin %?

Encore Medical EMI EBITDA Margin % is -25.71% as of Dec. 2025.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Encore Medical's EBITDA for the three months ended in Dec. 2025 was $-0.33 Mil. Encore Medical's Revenue for the three months ended in Dec. 2025 was $1.30 Mil. Therefore, Encore Medical's EBITDA margin for the quarter that ended in Dec. 2025 was -25.71%.

Encore Medical  (AMEX:EMI) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Encore Medical EBITDA Margin % Related Terms

Encore Medical EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Encore Medical's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Encore Medical EBITDA Margin % Chart

Encore Medical Annual Data
Trend Dec23 Dec24 Dec25
EBITDA Margin %
-95.26 -82.44 -31.83

Encore Medical Quarterly Data
Dec23 Sep24 Dec24 Jun25 Sep25 Dec25
EBITDA Margin % Get a 7-Day Free Trial -129.23 -110.66 0.00 -104.64 -25.71

EMI vs : EBITDA Margin % Comparison

For the Medical Instruments & Supplies subindustry, Encore Medical's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Encore Medical EBITDA Margin % vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Encore Medical's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Encore Medical's EBITDA Margin % falls into.


Encore Medical EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Encore Medical's EBITDA Margin % for the fiscal year that ended in Dec. 2025 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-0.823/2.586
=-31.83 %

Encore Medical's EBITDA Margin % for the quarter that ended in Dec. 2025 is calculated as

EBITDA Margin %=EBITDA (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=-0.333/1.295
=-25.71 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of -25.71% mean?
Encore Medical (EMI) has a EBITDA Margin % of -25.71% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Encore Medical and its competitors.
Is Encore Medical's EBITDA Margin % too high?
Encore Medical's current EBITDA Margin % is -25.71%.
How does Encore Medical's EBITDA Margin % compare to ?
Encore Medical's EBITDA Margin % of -25.71% can be compared against companies in the Medical Devices & Instruments industry. The industry median EBITDA Margin % is 7.48. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.48, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Encore Medical and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Encore Medical's current EBITDA Margin % is -25.71%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Encore Medical stock overvalued right now?
Encore Medical (EMI) has a current EBITDA Margin % of -25.71%. The current EBITDA Margin % is -25.71%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Encore Medical (EMI), the current EBITDA Margin % is -25.71% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Encore Medical Business Description

Comparable Companies
Address 2975 Lone Oak Drive, Suite 140, Eagan, MN, USA, 55121
Encore Medical Inc develops, manufactures, and markets septal occlusion devices for the repair of certain cardiac defects. Its products have been implanted in approximately 35,000 patients outside the United States. Its closure device is designed to correct a cardiac defect, generally diagnosed in adulthood, known as a patent foramen ovale (PFO). The company also currently market and sell septal occlusion devices for the transcatheter closure of atrial septal defects (ASD).